Connect with us

Business

GOLDSTEIN: Why does Trudeau not want us to see vaccine deals? – Toronto Sun

Published

 on


Article content

The fact Prime Minister Justin Trudeau and Procurement Minister Anita Anand refuse to disclose the contracts they’ve signed with vaccine manufacturers raises the question of what’s in them that they don’t want us to see.

They’ve rejected appeals from the opposition parties, Canada’s premiers and provincial public health experts to release the contracts on the grounds this would violate confidentiality provisions, which could lead to their cancellation.

But no one’s asking for information that would void the deals, for example about pricing. The concern is what do they say about the delivery schedule for vaccines.

That is, how many doses are part of each delivery, what is the timeline for delivery and what happens, if anything, if the manufacturers fail to meet quarterly targets in the contracts?

The provinces need this information to efficiently distribute vaccines.

We apologize, but this video has failed to load.

[embedded content]

So they know, for example, whether to release all the vaccines they receive immediately, confident more will arrive in time to administer the second dose within recommended time frames, or to hold back half the doses for the second inoculation, if it looks as if there will be more delays like the ones we’ve just experienced.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

It’s inexplicable why the Trudeau government has refused to disclose this information, at least to provincial public health officials, so they can prepare for what Trudeau and Anand say will be the delivery of six million vaccine doses by the end of March.

As Amir Attaran, professor of law and medicine at the University of Ottawa, recently told Global News:

“The federal government has been gaslighting Canadians on vaccines for months now with delivery timetables that are imperfectly disclosed, frequently changeable and bald assertions about how things will be okay without demonstrating the transparency to show why we should believe it will be okay.

“It’s unfair to the provinces, it’s very unfair to the healthcare workers who don’t exactly need additional stress after dragging the country along for a year … and … there’s very, very serious harm being done to Canadians’ mental health right now.”

While Trudeau said Friday the schedule of vaccine deliveries will be given to the provinces “soon,” all his government has disclosed to date is that it has spent more than $1 billion to obtain options to buy up to 402 million vaccine doses from Pfizer, Moderna, AstraZeneca, Medicago, Novavax, Sanofi and GlaxoSmithKline and Johnson & Johnson.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Only Pfizer and Moderna have been approved in Canada to date. All vaccines are two doses, except for Johnson & Johnson, which is a single dose.

We apologize, but this video has failed to load.

[embedded content]

On Friday, Liberal MPs on the Commons health committee used their favourite procedural trick — filibustering — to avoid passage of a Conservative motion seeking information on the contracts, supported by the Bloc Quebecois and the NDP.

According to Bloomberg’s vaccine tracker, Canada on Friday was in 39th place globally in the percentage of its population that has been vaccinated (3.23%), behind every other member of the G7 — U.S., U.K., Germany, France and Italy — except Japan.

Anand said Friday that Canada will receive 23 million doses of the two-dose Pfizer and Moderna vaccines by the end of June — enough to vaccinate 11.5 million people or 31% of Canada’s population of 37.59 million — and 84 million doses by the end of September, enough to inoculate every Canadian who wants to be vaccinated.

No vaccine has yet been recommended for children under the age of 16.

The European Union and the U.S. have released some vaccine contracts, albeit heavily redacted.

lgoldstein@postmedia.com

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Canada should invest in facilities to make vaccines for next pandemic, says Moderna co-founder – CTV News

Published

 on


[unable to retrieve full-text content]

  1. Canada should invest in facilities to make vaccines for next pandemic, says Moderna co-founder  CTV News
  2. Vaccines, excellent real world data  Dr. John Campbell
  3. COVID-19: Vaccinating B.C. kids could be critical to achieving herd immunity  Vancouver Sun
  4. Vaccine ‘ramp-up phase’: 1.3M Moderna doses in March; more than 10M Pfizer by June  CTV News
  5. Canada receives largest COVID-19 vaccine shipment to date | News  Daily Hive
  6. View Full coverage on Google News



Source link

Continue Reading

Business

Canadian Imperial Bank of Commerce profit beats estimates on capital market strength

Published

 on

TORONTO (Reuters) – Canadian Imperial Bank of Commerce beat analysts’ estimates for quarterly profit on Thursday, as it put aside lower-than-expected funds for loan loss provisions and its capital markets segment performed well.

Adjusted net income rose to C$1.64 billion, or C$3.58 a share, in the three months to Jan. 31, compared with C$1.5 billion, or C$3.24 a share, a year earlier. Analysts had expected C$2.81 a share, according to IBES data from Refinitiv.

Net income stood at C$1.63 billion, or C$3.55 a share, up from C$1.2 billion, or C$2.63 a share.

($1 = 1.2476 Canadian dollars)

 

(Reporting By Nichola Saminather and Sohini Podder; Editing by Shinjini Ganguli)

Continue Reading

Business

National Bank of Canada beats profit estimates on financial markets strength

Published

 on

(Reuters) – National Bank of Canada beat analysts’ estimates for first-quarter profit on Wednesday, as it set aside less capital to cover its loan losses and as earnings from its financial markets unit surpassed pre-pandemic levels.

Net income excluding one-off items rose to C$761 million ($605.41 million), or C$2.15 a share, in the three months through January, compared with C$620 billion, or C$1.70 a share, a year earlier. Analysts had expected C$1.71 a share, according to IBES data from Refinitiv.

 

 

(Reporting By Nichola Saminather and Sohini Podder; Editing by Amy Caren Daniel)

Continue Reading

Trending